While many of us remain indoors and practice social distancing, business opportunities, especially in the global pharmaceutical market, continue to grow at a rapid pace.
COVID-19 has forced many companies to evaluate, and implement cuts to their workforces, reductions in pay, benefits, and hours, or both.
The US DOJ announced in a business review letter its intent not to challenge an ongoing collaboration between numerous healthcare companies
COVID-19 (coronavirus) is naturally the focus of everyone’s attention currently given the unprecedented scale of the crisis.
The fraud triangle is a well-known tool in understanding fraud. The three sides – opportunity, incentive, and rationalization – offer an explanation to a person’s decision to commit fraud.
On March 30 and March 31, Alberta’s minister of environment and parks passed a slew of ministerial orders (the Orders) modifying certain industrial environmental reporting requirements in Alberta.
As the COVID-19 crisis deepens, the US medical system is facing significant uncertainty and is at risk of being overwhelmed.
Significant volume of material published by the UK regulators, the four key headlines.
March 2020 has seen a number of responses from the Government, regulators, associations and industry generally addressing issues and risks from the outbreak of the coronavirus (COVID-19). This update includes key regulatory responses in the wake of COVID-19 for the funds and financial services sector. Of the notable developments outside COVID-19, on 10 March 2020 the Australian Securities and Investments Commission (ASIC) published its new regulatory guidance on the foreign financial services providers licensing regime.
Practice area:
Industry:
Subscribe and stay up to date with the latest legal news, information and events . . .
Top
© Norton Rose Fulbright LLP 2023